oriconazole (VCZ) is considered first-line therapy for invasive aspergillosis and is often empirically prescribed to prevent the emergence of invasive fungal infections in patients undergoing a peripheral stem cell transplant (PSCT) (1, 2). In volunteers and patients, VCZ displays highly variable nonlinear pharmacokinetics, which are due primarily to polymorphic cytochrome P450 2C19 (CYP2C19) metabolism (3-6). Overall, the mean pharmacokinetic data of hematological-oncological patients are similar to those of healthy volunteers (7, 8) . After oral and intravenous administration, VCZ is extensively metabolized to inactive metabolites, including N-oxide VCZ, 4-hydroxy-VCZ, and dihydroxy-VCZ (5, 9, 10). The primary VCZ metabolite, Noxide VCZ, results from the N-oxidation of the fluoropyrimidine ring and accounts for 21% of the VCZ recovered dose (9). The formation of this metabolite is catalyzed primarily by CYP2C19 and CYP3A4 (9-12). VCZ pharmacokinetics are further influenced by the genetic polymorphisms of CYP2C19, other drugmetabolizing enzymes, and age-based differences in drug metabolism (10-17). The pharmacokinetics of VCZ have been studied, but those of N-oxide VCZ remain poorly characterized in PSCT patients. Therefore, the primary objective of this study was to characterize oral VCZ and N-oxide VCZ pharmacokinetics preand post-adult autologous PSCT.
men, all subjects received high-dose dexamethasone. Repeated blood sampling occurred 2 days following the loading dose (study day 3) and 6 days post-PSCT (study day 12) at predose and 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, and 12.0 h after the a.m. dose. All blood samples were analyzed in singlet by PPD/Pharmaco for analysis by high-performance liquid chromatography (HPLC) and mass spectrometry according to PPD method LCMS 244 V 2.00 (18) . The accuracy of data for the N-oxide VCZ assay was within the acceptable range for assay validation, but due to slow subject accrual, our sample age exceeded the stability of assay standards in the serum matrix. Thus, the true accuracy of the values for N-oxide VCZ was not guaranteed. Noncompartmental pharmacokinetic analysis of serum concentration data was performed using WinNonlin (Pharsight, St. Louis, MO). Statistical significance was defined a priori as an ␣ value of Յ0.05. Statistical analysis was performed with NCSS 2001 (Number Cruncher Statistical Systems, Kaysville, UT).
In the study, 14 patients were enrolled, but only 10 patients (6 males) completed both pharmacokinetic sampling periods (day 3 and day 12), and only those are presented. The demographics of the 10 patients who completed both VCZ sampling arms are provided in Table 1 , and the mean VCZ and N-oxide VCZ plasma concentration-time curves on days 3 and 12 are displayed in Fig. 1 . Male and female subjects differed significantly for weight, height, mg/kg of body weight/dose, and mg/kg/day, but the body mass index (BMI) did not significantly differ between the genders. VCZ and N-oxide VCZ pharmacokinetics demonstrated considerable interpatient variability. Overall, on days 3 and 12, VCZ pharmacokinetic parameters were not significantly different ( Table 2 ). On days 3 and 12, the mean VCZ concentrations at hour 12 (C 12 ) were 1.58 g/ml (range, 0.135 to 3.63 g/ml) and 1.84 g/ml (range, 0.09 to 3.89 g/ml), respectively (P ϭ 0.4). The primary metabolite N-oxide VCZ demonstrated significant pharmacokinetic changes between days 3 and 12 ( Table 2) . Parent-to-metabolite (VCZ/N-oxide VCZ) ratios were also compared for the maximum concentration of the drug (C max ) and the area under the concentration-time curve from 0 to 12 hours (AUC 0-12 ) on days 3 and 12 ( Table 2 ). Day 12 VCZ/N-oxide ratios for C max and AUC 0-12 were increased by 50% and 47.5%, respectively, compared to day 3.
The pharmacokinetic values of oral VCZ in our study are consistent with those of previous multiple-dose studies that used a loading dose (19, 20) . Therefore, our data suggest that the standard oral VCZ dosing regimen is sufficient to adequately maintain prophylactic VCZ serum concentrations and exposure in most patients pre-and post-PSCT. Moreover, dosages recommended by approved labeling for adults achieved adequate mean C 12 values on days 3 and 12 for prophylaxis (Ͼ0.5 g/ml). However, given the range of C 12 values observed, standard dosing may be inadequate for the treatment of invasive infections and may even be insufficient for prophylaxis in certain patients (21, 22) . Unlike VCZ, the N-oxide VCZ pharmacokinetic values were all significantly decreased on day 12 compared to day 3. Because there were no significant pharmacokinetic changes in the parent compound during the study period, the significant changes in N-oxide VCZ pharmacokinetics are intriguing and are most likely due to further metabolism via other CYP enzymes (5, (9) (10) (11) (12) . N-Oxide VCZ formation involves primarily CYP2C19 and CYP3A4 (5, 10, 11) . The formation rate of N-oxide VCZ at high (2,500 M) and low (25 M) VCZ concentrations involves CYP3A4 and CYP2C19, respectively (10, 11) . VCZ concentrations measured in this study were well in excess of 25 M, a finding which suggests that CYP3A4 catalyzed N-oxide VCZ formation. Given the primary role of CYP3A4 in N-oxide VCZ formation and that the observed VCZ concentrations were similar on days 3 and 12, it is reasonable to assume similar rates of formation of N-oxide VCZ on days 3 and 12 and that its concentrations would also be unchanged. However, our results demonstrated a significant reduction in Noxide VCZ between days 3 and 12. Therefore, the reductions in the formation of N-oxide VCZ observed on day 12 may reflect the formation of other metabolites that were not measured in this study (9) . Alternatively, these reductions may reflect the unavoid- able consequence of our patients receiving high-dose dexamethasone, which is known to activate glucocorticoid receptor (GR). GR activation can increase the transcription of CYP2C19 and CYP3A4 enzyme gene expression and possibly induction effects (23) . Visual inspection of our VCZ serum concentrations does not suggest induction between days 3 and 12, but others have observed VCZ induction (24) . To our knowledge, this is the first report of VCZ/N-oxide ratios with repeated dosing in patients without interacting medications. The day-3 ratios in this study are consistent with those of two other steady-state oral VCZ studies that compared VCZ and the N-oxide metabolite (19, 20) . In a third study, the ratios for C max and AUC 0-12 were lower than ours (25) . However, that study was performed only in adult females who were considerably younger than our subjects (mean of 25.9 years versus 67.1 years, respectively). While the sex differences between the study populations may have contributed to the differences in parent-to-metabolite ratios, the effect of sex on CYP2C19 is inconclusive (26) . Lastly, the reductions may reflect analytical artifact. Nonetheless, while the accuracy of the metabolite concentrations in this study cannot be guaranteed, the serum N-oxide VCZ concentrations, pharmacokinetic values, and parent drug/metabolite ratios we obtained are consistent with those measured by others employing a similar regimen (7, 8, 13, 19, 20, 25) . Moreover, assay precision is not affected by sample age and was within the acceptable range for assay performance. Therefore, our data suggest that a decline in N-oxide VCZ serum concentrations occurred between days 3 and 12, but the exact values and magnitude of that decline cannot be reliably characterized by our study.
In conclusion, our data suggest that the standard VCZ oral loading and maintenance dosing regimens are sufficient to maintain prophylactic VCZ serum concentrations and exposure in most patients pre-and post-PSCT. However, we noted a significant decline in N-oxide VCZ serum concentrations and pharmacokinetic values. Although this finding is interesting, the clinical significance and metabolic implications of these changes need further study. 
